HomeQuestion

With emerging therapies, what is your general treatment ladder for chronic spontaneous urticaria (CSU)?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Does baseline facial dermatitis in a patient with AD cause hesitation when starting Dupixent due to conjunctivitis-related complications, especially when there are many available options?

What role do you feel topical steroids play in the management of atopic dermatitis with the growing availability of non-steroid topicals?

How do you counsel patients with chronic urticaria on the role of stress management strategies in their treatment plan?

How long do you apply patch testing before interpreting the results?

What factors do you weigh most heavily when deciding on the duration of treatment with dupilumab in a patient with atopic dermatitis who is responding well and tolerating therapy?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.